Results 31 to 40 of about 61,476 (246)

CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data

Acta Neuropathologica Communications, 2023
Homozygous CDKN2A/B deletion has been associated with an increased risk of recurrence in meningiomas. However, the evidence is confined to a limited number of studies, and the importance of heterozygous CDKN2A/B deletions remains insufficiently ...
Johannes Wach, Alim Emre Basaran, Felix Arlt, Martin Vychopen, Clemens Seidel, Alonso Barrantes-Freer, Wolf Müller, Frank Gaunitz, Erdem Güresir   +8 more
doaj   +1 more source

Cyclin Dependent Kinase Inhibitor 2A Genetic and Epigenetic Alterations Interfere with Several Immune Components and Predict Poor Clinical Outcome

Biomedicines, 2023
Cyclin dependent kinase inhibitor 2A (CDKN2A) is a well-known tumor suppressor gene as it functions as a cell cycle regulator. While several reports correlate the malfunction of CDKN2A with the initiation and progression of several types of human tumors,
Mohamed A. Soltan, Ahmad A. Alhanshani, Ayed A. Shati, Youssef A. Alqahtani, Dalal Sulaiman Alshaya, Jawaher Alharthi, Sarah Awwadh Altalhi, Eman Fayad, Mohamed Samir A. Zaki, Refaat A. Eid   +9 more
doaj   +1 more source

CDKN2A analysis results.

, 2013
Immunohistochemistry (IHC) was performed using standard protocol on formalin-fixed paraffin-embedded tumor specimen to assess for expression of CDKN2A (9p21.3). Methylation specific PCR was
Zhenfeng Duan (206175), Dafydd Thomas (118889), Andrew Eric Rosenberg (351550), Vikram Deshpande (351552), Joseph Schwab (351553), G. Petur Nielsen (351549), Francis J. Hornicek (248438), Long Phi Le (192047), Julie M. Batten (351551), A. John Iafrate (128597), Ramnik J. Xavier (153776)   +10 more
core   +1 more source

CDKN2a (cyclin dependent kinase 2a / p16) [PDF]

, 2008
Review on CDKN2a (cyclin dependent kinase 2a / p16), with data on DNA, on the protein encoded, and where the gene is ...
Lemoine, A, Debuire, B, Saffroy, R
core   +1 more source

CDKN2A Deletion in Melanoma Excludes T Cell Infiltration by Repressing Chemokine Expression in a Cell Cycle-Dependent Manner

Frontiers in Oncology, 2021
T-cell-mediated immune response is the prerequisite for T-cell-based immunotherapy. However, the limitation of T-cell infiltration in solid tumors restricted the therapeutic effect of T-cell-based immunotherapy.
Zhen Zhu, Hao Song, Juan Xu
doaj   +1 more source

Aberrant methylation of CDKN2A, RASSF1A and WIF1 in sporadic adenocarcinomatous colorectal cancer: Associations with clinicopathological features

Journal of Advanced Biotechnology and Experimental Therapeutics, 2021
Accumulating evidence support that aberrant methylation of various cancer-related genes plays an important role in the initiation and progression of colorectal cancer (CRC).
Linh Dieu Vuong, Hung Viet Nguyen, Van-Long Truong, Quang Ngoc Nguyen   +3 more
doaj   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

FOXA1 and CDKN2A.

, 2014
Protein expression of FOXA1 is significantly associated with CDKN2A mRNA expression in metastases, but not in primary tumors.
Camilla Krakstad (106761), Antoni Hurtado (238167), Kjell Petersen (69736), Ingvild Løberg Tangen (567161), Henrica M. J. Werner (527344), Lars A. Akslen (158246), Mari K. Halle (527345), Helga B. Salvesen (184697), Kanthida Kusonmano (106767), Jone Trovik (106797), Karl Henning Kalland (567162), Anne M. Øyan (106784)   +11 more
core   +1 more source

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

FEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos, Antonia Petropoulou, Alexandra Anastogianni, Angelina Bania, Vassilis Stamatakis, Argyris Alexiou, Chi‐Ping Day, Glenn Merlino, Katerina Grafanaki, Constantinos Stathopoulos   +9 more
wiley   +1 more source

CDKN2A/p16 is inactivated in most melanoma cell lines [PDF]

, 1997
The CDKN2A gene maps to chromosome 9p21-22 and is responsible for melanoma susceptibility in some families. Its product, p16, binds specifically to CDK4 and CDK6 in vitro and in vivo, inhibiting their kinase activity.
Castellano, Marina, Pollock, Pamela M., Sparrow, Louise E., Gabrielli, Brian G., Parsons, Peter G., Walters, Marilyn K., Down, Louise M., Hayward, Nicholas K.   +7 more
core